Telomir Pharmaceuticals Reports Preclinical Data Showing Telomir-Zn Benefits in Wilson’s Disease Model
Telomir Pharmaceuticals announced peer-reviewed preclinical data demonstrating that Telomir-Zn improved survival and reduced oxidative stress and copper burden in a Wilson’s disease model, expanding the drug’s potential beyond its lead cancer program.
Telomir Pharmaceuticals (NASDAQ: TELO) has published peer-reviewed preclinical data in Advances in Redox Research showing that its lead compound, Telomir-Zn, delivered dose-dependent survival improvements and multiple therapeutic benefits in a Wilson’s disease model. The findings, announced in a press release, indicate that Telomir-Zn reduced oxidative stress, lowered hepatic copper burden, and improved liver function markers, supporting its biological activity in Wilson’s disease.
Wilson’s disease is a genetic disorder characterized by copper accumulation in the liver and brain, leading to organ damage. Current treatments focus on chelation therapy or zinc supplementation to reduce copper levels, but they often have limited efficacy or tolerability. The preclinical results suggest that Telomir-Zn may offer a novel therapeutic approach by modulating intracellular metal homeostasis and redox balance.
This data expands the scientific validation for Telomir-Zn, which is also the company’s lead candidate in its triple-negative breast cancer program. Telomir Pharmaceuticals is advancing that program toward Phase 1/2 clinical initiation. The company’s platform targets fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. Beyond Wilson’s disease, Telomir-Zn has shown activity in preclinical studies involving modulation of mitochondrial function, genomic stability, and epigenetically regulated gene expression.
The implications of these findings are significant for Telomir Pharmaceuticals, as they demonstrate the potential versatility of its lead compound. A successful application in Wilson’s disease could open new markets and validate the broader therapeutic utility of the company’s small-molecule approach. For investors, the data provides additional evidence of the drug’s biological activity, which may de-risk the development pipeline. For patients with Wilson’s disease, if these results translate to humans, Telomir-Zn could offer a new treatment option that addresses underlying disease mechanisms more effectively than current therapies.
The company notes that the data were peer-reviewed, adding credibility to the findings. Telomir Pharmaceuticals continues to evaluate Telomir-Zn in various indications, with a focus on advancing its lead oncology program while exploring additional applications. More information about the company and its research can be found in its newsroom.